Yahoo Finance Dr. Martens Full Year 2024 Earnings: Misses Expectations
Dr. Martens (LON:DOCS) Full Year 2024 Results
Key Financial Results
Revenue: UK£877.1m (down 12% from FY 2023).
Net income: UK£69.2m (down 46% from FY 2023).
Profit margin: 7.9% (down from 13% in FY 2023). The decrease in margin was driven by lower revenue.
EPS: UK£0.07 (down from UK£0.13 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Dr. Martens Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 1.9%.
The primary driver behind last 12 months revenue was the EMEA segment contributing a total revenue of UK£431.8m (49% of total revenue). The largest operating expense was General & Administrative costs, amounting to UK£377.7m (75% of total expenses). Explore how DOCS's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Luxury industry in Europe.
Performance of the market in the United Kingdom.
The company's shares are down 5.9% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Dr. Martens, and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
